Tonix Pharmaceuticals Holding Corp.TNXPEarnings & Financial Report
Tonix Pharmaceuticals is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project.
TNXP Q4 FY2025 Key Financial Metrics
Revenue
$5.4M
Gross Profit
$4.3M
Operating Profit
$-48.3M
Net Profit
$-46.9M
Gross Margin
80.4%
Operating Margin
-895.8%
Net Margin
-870.3%
YoY Growth
108.8%
EPS
$-4.28
Tonix Pharmaceuticals Holding Corp. Q4 FY2025 Financial Summary
Tonix Pharmaceuticals Holding Corp. reported revenue of $5.4M (up 108.8% YoY) for Q4 FY2025, with a net profit of $-46.9M (down 112.2% YoY) (-870.3% margin). Cost of goods sold was $1.1M, operating expenses totaled $52.6M.
Key Financial Metrics
| Total Revenue | $5.4M |
|---|---|
| Net Profit | $-46.9M |
| Gross Margin | 80.4% |
| Operating Margin | -895.8% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Tonix Pharmaceuticals Holding Corp. Q4 FY2025 revenue of $5.4M breaks down across 2 segments, led by Zembrace Symtouch at $3.1M (58.2% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Zembrace Symtouch | $3.1M | 58.2% |
| Other | $2.3M | 41.8% |
Tonix Pharmaceuticals Holding Corp. Revenue by Segment — Quarterly Trend
Tonix Pharmaceuticals Holding Corp. revenue by segment across the last 4 reported quarters, showing how each business line (such as Zembrace Symtouch and Other) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Zembrace Symtouch | $3.1M | $2.6M | $1.6M | $2.0M |
| Other | $2.3M | $708.0K | $428.0K | $403.0K |
Tonix Pharmaceuticals Holding Corp. Annual Revenue by Year
Tonix Pharmaceuticals Holding Corp. annual revenue history includes year-by-year totals (for example, 2025 revenue was $13.1M).
Tonix Pharmaceuticals Holding Corp. Quarterly Revenue & Net Profit History
Tonix Pharmaceuticals Holding Corp. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $5.4M | +108.8% | $-46.9M | -870.3% |
| Q3 FY2025 | $3.3M | +16.6% | $-32.0M | -972.9% |
| Q2 FY2025 | $2.0M | -9.5% | $-28.3M | -1415.0% |
| Q1 FY2025 | $2.4M | -2.1% | $-16.8M | -692.8% |
| Q4 FY2024 | $2.6M | — | $-22.1M | -856.2% |
| Q3 FY2024 | $2.8M | -29.3% | $-14.2M | -503.6% |
| Q2 FY2024 | $2.2M | — | $-78.8M | -3567.8% |
| Q1 FY2024 | $2.5M | — | $-14.9M | -601.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5M | $2.2M | $2.8M | $2.6M | $2.4M | $2.0M | $3.3M | $5.4M |
| YoY Growth | N/A | N/A | -29.3% | N/A | -2.1% | -9.5% | 16.6% | 108.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $135.3M | $70.3M | $95.0M | $162.9M | $192.9M | $187.4M | $252.4M | $277.2M |
| Liabilities | $27.2M | $28.2M | $20.8M | $23.3M | $12.5M | $19.4M | $21.3M | $32.0M |
| Equity | $108.1M | $42.1M | $74.2M | $139.6M | $180.4M | $168.0M | $231.1M | $245.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-17.6M | $-9.9M | $-18.8M | $-14.6M | $-16.6M | $-14.8M | $-28.8M | $-39.6M |